BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

- As previously announced, the primary endpoint was met with a highly statistically significant p-value - The placebo and acoramidis time-to-first event Kaplan-Meier curves for a composite of...

Related Keywords

United States ,Ukraine ,American ,Vikram Bali ,Exchange Commission ,Bio Pharma Inc ,Twitter ,European Society Of Cardiology Congress ,Nasdaq ,Securities Exchange ,American Heart Association ,Bridgebio Pharma Inc ,Steering Committee ,Linkedin ,Drug Administration ,University Of South Carolina ,Win Ratio ,Hazard Ratio ,New Drug Application ,Bio Pharma ,Scientific Sessions ,European Society ,Cardiology Congress ,Daniel Judge ,Medical University ,South Carolina ,Bridgebio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Risk Factors ,Annual Report ,Bio Media Contact ,Markets ,